ArticleJournal of drug assessment2019

Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis.

Cristian Gheorghe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.